
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read more
- Annual report 2019PDF - 4.1MB
We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Every day, we help improve the health of millions of people around the world.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
Our values and expectations are at the heart of everything we do - so that together we can deliver extraordinary impact for our patients and consumers and make GSK a brilliant place to work.
Our values are Patient focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.
What we do
We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.
Pharmaceuticals

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients.
Vaccines

We are the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. Our R&D focuses on developing vaccines against infectious diseases that combine high medical need and strong market potential.
Consumer Healthcare

Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more
How we do it
Everyone at GSK is focused on our 3 long-term priorities – Innovation, Performance, Trust, all powered by our performance-focused culture.
Innovation
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.
-
£4.3bn
adjusted R&D investment in 2019
-
40
new medicines in development at Q3 2020
-
18
new vaccines in development at Q3 2020
Performance
We deliver growth by investing effectively in our business, developing our people and executing competitively.
-
£33.8bn
turnover in 2019
-
£9bn
adjusted operating profit in 2019
-
£5.1bn
free cash flow in 2019
-
£4bn
dividends paid in 2019
Trust
We are a responsible company - using our science and technology to address health needs, we are focused on making our products affordable and available, and being a modern employer.
-
78%
employee engagement score on our latest employee survey
-
£263m
donated in 2019 to community health programmes
-
1st
in Access to Medicines Index since the assessment began in 2008
Find out more about us
-
Our history
-
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
-
Board of Directors
The Board of Directors is responsible for the group's system of corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance.
-
Governance
At GSK we are committed to operating at the highest standards of corporate governance.
-
Policies, codes and standards
Find out more about the GSK Code of Conduct and our Anti-Bribery and Corruption programme